Circulating biomarker responses to medical management vs. mechanical circulatory support in severe inotrope-dependent acute heart failure

ESC Heart Failure

Volumn 3, Issue 2, 2016, Pages 86-96

  Meredith, Anna J ^a,b   Dai, Darlene L Y ^b   Chen, Virginia ^b   Hollander, Zsuzsanna ^b   Ng, Raymond ^a,b   Kaan, Annemarie ^a   Tebbutt, Scott ^a,b   Ramanathan, Krishnan ^a   Cheung, Anson ^a   McManus, Bruce M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PROOF Centre of Excellence   (Canada)

Author keywords

Acute heart failure; Bioinformatics; Biomarkers; Mechanical circulatory support; Plasma proteomics; Ventricular assist device

Indexed keywords

EID: 85031291843     PISSN: None     EISSN: 20555822     Source Type: Journal    
DOI: 10.1002/ehf2.12076     Document Type: Article

References (39)

1. Gackowski A, Isnard R, Golmard JL, Pousset F, Carayon A, Montalescot G, Hulot JS, Thomas D, Piwowarska W, Komajda M. Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 2004; 25: 1788–1796
2. Formica P, Murthy S, Edwards P, Goldstein D, Maybaum S. A structured 3-step approach to evaluate cardiac recovery with continuous flow circulatory support. J Heart Lung Transplant 2010; 29: 1440–1442
3. Heise G, Lemmer J, Weng Y, Hubler M, Alexi-Meskishvili V, Bottcher W, Hetzer R, Berger F, Stiller B. Biomarker responses during mid-term mechanical cardiac support in children. J Heart Lung Transplant 2008; 27: 150–157
4. Sodian R, Loebe M, Schmitt C, Potapov EV, Siniawski H, Muller J, Hausmann H, Zurbruegg HR, Weng Y, Hetzer R. Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. J Am Coll Cardiol 2001; 38: 1942–1949
5. Kuzyk MA, Smith D, Yang J, Cross TJ, Jackson AM, Hardie DB, Anderson NL, Borchers CH. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009; 8: 1860–1877
6. Domanski D, Percy AJ, Yang J, Chambers AG, Hill JS, Freue GVC, Borchers CH. MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics 2012; 12: 1222–1243
7. Development Core Team R. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2005
8. Cohen Freue GV, Meredith A, Smith D, Bergman A, Sasaki M, Lam KK, Hollander Z, Opushneva N, Takhar M, Lin D, Wilson-McManus J, Balshaw R, Keown PA, Borchers CH, McManus B, Ng RT, McMaster WR, Biomarkers in T, the NCECPoOFCoET. Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation. PLoS Comput Biol 2013; 9: e1002963
9. Lin D, Cohen Freue G, Hollander Z, John Mancini GB, Sasaki M, Mui A, Wilson-McManus J, Ignaszewski A, Imai C, Meredith A, Balshaw R, Ng RT, Keown PA, Robert McMaster W, Carere R, Webb JG, McManus BM. Plasma protein biosignatures for detection of cardiac allograft vasculopathy. J Heart Lung Transplant 2013; 32: 723–733
10. Lin D, Hollander Z, Ng RT, Imai C, Ignaszewski A, Balshaw R, Freue GC, Wilson-McManus JE, Qasimi P, Meredith A, Mui A, Triche T, McMaster R, Keown PA, McManus BM. Whole blood genomic biomarkers of acute cardiac allograft rejection. J Heart Lung Transplant 2009; 28: 927–935
11. Shah NR, Bieniarz MC, Basra SS, Paisley RD, Loyalka P, Gregoric ID, Mann DL, Kar B. Serum biomarkers in severe refractory cardiogenic shock. JACC: Heart Failure 2013; 1: 200–206
12. Kalogeropoulos AP, Tang WH, Hsu A, Felker GM, Hernandez AF, Troughton RW, Voors AA, Anker SD, Metra M, McMurray JJ, Massie BM, Ezekowitz JA, Califf RM, O'Connor CM, Starling RC, Butler J. High sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. J Card Fail 2014; 20: 319–26
13. Wollert KC, Taga T, Saito M, Narazaki M, Kishimoto T, Glembotski CC, Vernallis AB, Heath JK, Pennica D, Wood WI, Chien KR. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem 1996; 271: 9535–9545
14. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross J Jr, Muller W, Chien KR. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999; 97: 189–198
15. Zolk O, Ng LL, O'Brien RJ, Weyand M, Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation 2002; 106: 1442–1446
16. Lopez N, Varo N, Diez J, Fortuno MA. Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists? Cardiovasc Res 2007; 75: 536–545
17. Limongelli G, Roselli T, Pacileo G, Calabro P, Maddaloni V, Masarone D, Riegler L, Gravino R, Scarafile R, Salerno G, Miele T, D'Andrea A, Santangelo L, Romano M, Di Salvo G, Russo MG, Calabro R. Effect of cardiac resynchronization therapy on cardiotrophin-1 circulating levels in patients with heart failure. Intern Emerg Med 2014; 9: 43–50
18. Al-Mazroua HA, Al-Rasheed NM, Korashy HM. Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection. J Cardiovasc Pharmacol 2013; 61: 337–344
19. Bergmann MW. WNT signaling in adult cardiac hypertrophy and remodeling: lessons learned from cardiac development. Circ Res 2010; 107: 1198–1208
20. Malekar P, Hagenmueller M, Anyanwu A, Buss S, Streit MR, Weiss CS, Wolf D, Riffel J, Bauer A, Katus HA, Hardt SE. Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling. Hypertension 2010; 55: 939–945
21. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116: 1482–1487
22. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010; 56: 225–231
23. Mahajan VS, Jarolim P. How to interpret elevated cardiac troponin levels. Circulation 2011; 124: 2350–2354
24. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Astor BC, Mosley TH, Folsom AR, Heiss G, Coresh J, Ballantyne CM. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011; 123: 1367–1376
25. Liquori ME, Christenson RH, Collinson PO, Defilippi CR. Cardiac biomarkers in heart failure. Clin Biochem 2014; 47: 327–337
26. Miller WL, Hartman KA, Burritt MF, Burnett JC Jr, Jaffe AS. Troponin, B-type natriuretic peptides and outcomes in severe heart failure: differences between ischemic and dilated cardiomyopathies. Clin Cardiol 2007; 30: 245–250
27. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503–2512
28. Lowbeer C, Gustafsson SA, Seeberger A, Bouvier F, Hulting J. Serum cardiac troponin T in patients hospitalized with heart failure is associated with left ventricular hypertrophy and systolic dysfunction. Scand J Clin Lab Invest 2004; 64: 667–676
29. Ago T, Sadoshima J. GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res 2006; 98: 294–297
30. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H, Anker SD, Wollert KC. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1054–1060
31. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006; 98: 351–360
32. Lok SI, Winkens B, Goldschmeding R, van Geffen AJ, Nous FM, van Kuik J, van der Weide P, Klopping C, Kirkels JH, Lahpor JR, Doevendans PA, de Jonge N, de Weger RA. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 2012; 14: 1249–1256
33. McLaughlin L, Zhu G, Mistry M, Ley-Ebert C, Stuart WD, Florio CJ, Groen PA, Witt SA, Kimball TR, Witte DP, Harmony JA, Aronow BJ. Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. J Clin Invest 2000; 106: 1105–1113
34. Miyata M, Biro S, Kaieda H, Eto H, Orihara K, Kihara T, Obata H, Matsushita N, Matsuyama T, Tei C. Apolipoprotein J/clusterin is induced in vascular smooth muscle cells after vascular injury. Circulation 2001; 104: 1407–1412
35. Cubedo J, Padro T, Garcia-Moll X, Pinto X, Cinca J, Badimon L. Proteomic signature of Apolipoprotein J in the early phase of new-onset myocardial infarction. J Proteome Res 2011; 10: 211–220
36. Manzano-Fernandez S, Januzzi JL, Pastor-Perez FJ, Bonaque-Gonzalez JC, Boronat-Garcia M, Pascual-Figal DA, Montalban-Larrea S, Navarro-Penalver M, Andreu-Cayuelas JM, Valdes M. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology 2012; 122: 158–166
37. Caselli C, D'Amico A, Ragusa R, Caruso R, Prescimone T, Cabiati M, Nonini S, Marraccini P, Del Ry S, Trivella MG, Parodi O, Giannessi D. IL-33/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators? Mediators Inflamm 2013; 2013: 498703
38. Breidthardt T, Balmelli C, Twerenbold R, Mosimann T, Espinola J, Haaf P, Thalmann G, Moehring B, Mueller M, Meller B, Reichlin T, Murray K, Ziller R, Benkert P, Osswald S, Mueller C. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J Card Fail 2013; 19: 821–828
39. Kemkes-Matthes B, Matthes KJ. Protein Z deficiency: a new cause of bleeding tendency. Thromb Res 1995; 79: 49–55